A one-time infusion of an in vivo gene-editing treatment vs. placebo reduced the monthly rate of hereditary angioedema attacks in patients aged 16 years and older, according to results published in The New England Journal of Medicine.These data on investigational lonvoguran ziclumeran (lonvo-z, Intellia Therapeutics) were simultaneously presented at the 2026 European Academy of Allergy &